20 July 2020
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
26 June 2020
The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
15 June 2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
1 June 2020
Stéphane Paulus and Else Bijker explore the topic in their article for The Conversation.
22 May 2020
Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
30 April 2020
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
24 April 2020
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
Paediatrics project receives funding to assess novel coronavirus infection rates in children and teenagers across the UK
20 April 2020
A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.
Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children
17 April 2020
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
27 March 2020
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.